Provides subcutaneous immunoglobulin antibody replacement therapy for individuals with primary or secondary immune deficiency.
Patients must have a confirmed diagnosis involving primary or secondary immune deficiency. The patient or caregiver who will be infusing the patient must be capable of being trained to administer subcutaneous immunoglobulin safely and accurately in the home setting. subcutaneous immunoglobulin is a blood product with associated risks, and the patient or guardian must provide written informed consent to subcutaneous immunoglobulin home infusion.
The patient or guardian must also agree in writing to complete and submit infusion logs. Finally, the patient must have access to a working telephone, and to rapidly available emergency assistance, if needed.
For patients aged 3 and over.